CPC A61K 39/04 (2013.01) [A61K 35/15 (2013.01); A61K 39/001119 (2018.08); A61K 39/00114 (2018.08); A61K 39/39 (2013.01); A61K 39/4615 (2023.05); A61K 39/4622 (2023.05); A61K 39/4644 (2023.05); A61K 2039/515 (2013.01); A61K 2039/585 (2013.01)] | 18 Claims |
1. A method of treating cancer comprising:
a) administering to a subject having cancer an effective dose of Bacillus Calmette-Guerin (BCG) and an IL-15:IL-15Rα fusion protein complex;
b) isolating immune effector cells from a biological sample of the subject following step a, wherein the immune effector cells comprise antigen presenting cells, CD8+ T cells, and natural killer (NK) cells;
c) culturing the immune effector cells with a composition comprising the IL-15:IL-15Rα fusion protein complex; and
d) reinfusing the cultured immune effector cells into the subject, thereby treating the cancer.
|